Details for New Drug Application (NDA): 021224
✉ Email this page to a colleague
The generic ingredient in RAZADYNE is galantamine hydrobromide. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the galantamine hydrobromide profile page.
Summary for 021224
Tradename: | RAZADYNE |
Applicant: | Janssen Pharms |
Ingredient: | galantamine hydrobromide |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021224
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;ORAL | Strength | 4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jun 22, 2001 | TE: | RLD: | No |
Expired US Patents for NDA 021224
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Janssen Pharms | RAZADYNE | galantamine hydrobromide | SOLUTION;ORAL | 021224-001 | Jun 22, 2001 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription